TITLE: PBMC- 01a - Isolation of Human PBMC from Buffy Coat
AUTHORS: Marco Cosentino, Elisa Storelli, Alessandra Luini, Massimiliano Legnaro, Emanuela Rasini, Marco Ferrari, Franca Marino

[DESCRIPTION]
<div class = "text-blocks"><div class = "text-block"><span style = "font-weight:bold;">List of published work using this protocol</span></div><div class = "text-block"><ul style = "list-style-type:disc;"><li style = "counter-reset:ol0;list-style-type:disc;"><span>Kustrimovic, N., Comi, C., Magistrelli, L., Rasini, E., Legnaro, M., Bombelli, R., Aleksic, I., Blandini, F., Minafra, B., Riboldazzi, G., Sturchio, A., Mauri, M., Bono, G., Marino, F., & Cosentino, M. (2018). Parkinson's disease patients have a complex phenotypic and functional Th1 bias: cross-sectional studies of CD4+ Th1/Th2/T17 and Treg in drug-naïve and drug-treated patients. Journal of neuroinflammation, 15(1), 205. </span><a href="https://doi.org/10.1186/s12974-018-1248-8" style = "text-decoration:underline;color:blue;cursor:pointer;"><span style = ":;:UNDERLINE;">https://doi.org/10.1186/s12974-018-1248-8</span></a><span style = ":;:UNDERLINE;"></span></li><li style = "counter-reset:ol0;list-style-type:disc;"></li><li style = "counter-reset:ol0;list-style-type:disc;"></li><li style = "counter-reset:ol0;list-style-type:disc;"><span>Kustrimovic, N., Rasini, E., Legnaro, M., Bombelli, R., Aleksic, I., Blandini, F., Comi, C., Mauri, M., Minafra, B., Riboldazzi, G., Sanchez-Guajardo, V., Marino, F., & Cosentino, M. (2016). Dopaminergic Receptors on CD4+ T Naive and Memory Lymphocytes Correlate with Motor Impairment in Patients with Parkinson's Disease. Scientific reports, 6, 33738. </span><a href="https://doi.org/10.1038/srep33738" style = "text-decoration:underline;color:blue;cursor:pointer;"><span style = ":;">https://doi.org/10.1038/srep33738</span></a></li><li style = "counter-reset:ol0;list-style-type:disc;"></li><li style = "counter-reset:ol0;list-style-type:disc;"></li><li style = "counter-reset:ol0;list-style-type:disc;"><span>Cosentino M., Ferrari M., Kustrimovic N., Rasini E., Marino F. (2015). Influence of dopamine receptor gene polymorphisms on circulating T lymphocytes: A pilot study in healthy subjects. Human immunology, 76, 10, 747-752. </span><a href="https://doi.org/10.1016/j.humimm.2015.09.032" style = "text-decoration:underline;color:blue;cursor:pointer;"><span style = ":;">https://doi.org/10.1016/j.humimm.2015.09.032</span></a></li></ul></div><div class = "text-block"><ul style = "list-style-type:disc;"><li style = "counter-reset:ol0;list-style-type:disc;"><span>Kustrimovic, N., Rasini, E., Legnaro, M., Bombelli, R., Aleksic, I., Blandini, F., Comi, C., Mauri, M., Minafra, B., Riboldazzi, G., Sanchez-Guajardo, V., Marino, F., & Cosentino, M. (2016). Dopaminergic Receptors on CD4+ T Naive and Memory Lymphocytes Correlate with Motor Impairment in Patients with Parkinson's Disease. Scientific reports, 6, 33738. </span><a href="https://doi.org/10.1038/srep33738" style = "text-decoration:underline;color:blue;cursor:pointer;"><span style = ":;">https://doi.org/10.1038/srep33738</span></a></li><li style = "counter-reset:ol0;list-style-type:disc;"></li><li style = "counter-reset:ol0;list-style-type:disc;"></li><li style = "counter-reset:ol0;list-style-type:disc;"><span>Cosentino M., Ferrari M., Kustrimovic N., Rasini E., Marino F. (2015). Influence of dopamine receptor gene polymorphisms on circulating T lymphocytes: A pilot study in healthy subjects. Human immunology, 76, 10, 747-752. </span><a href="https://doi.org/10.1016/j.humimm.2015.09.032" style = "text-decoration:underline;color:blue;cursor:pointer;"><span style = ":;">https://doi.org/10.1016/j.humimm.2015.09.032</span></a></li></ul></div><div class = "text-block"><ul style = "list-style-type:disc;"></ul></div></div>

[STEPS]
?. Put the needed amount of blood sample from buffy coat into a 50 ml conical tube.
?. Add an equal volume of PBS 1X and mix well.
{"blocks":[{"key":"6d8lo","text":"This recepe is used in the following protocols:","type":"unstyled","depth":0,"inlineStyleRanges":[],"entityRanges":[],"data":[]},{"key":"9q3hu","text":"\n","type":"unstyled","depth":0,"inlineStyleRanges":[],"entityRanges":[],"data":[]},{"key":"aot8v","text":"- Separation and purification of human PBMC from FRESH BLOOD","type":"unstyled","depth":0,"inlineStyleRanges":[],"entityRanges":[],"data":[]},{"key":"12app","text":"- Separation and purification of human PBMC from BUFFY COAT","type":"unstyled","depth":0,"inlineStyleRanges":[],"entityRanges":[],"data":[]},{"key":"fca5s","text":"- Magnetic bead-based CD4+ T cell isolation from PBMCs with Dynabeads: CD4 Positive Isolation Kit","type":"unstyled","depth":0,"inlineStyleRanges":[],"entityRanges":[],"data":[]},{"key":"10nas","text":"- Magnetic bead-based TREG-TEFF cell isolation from PBMC with Miltenyi CD4+CD25+ Regulatory T cell Isolation Kit","type":"unstyled","depth":0,"inlineStyleRanges":[],"entityRanges":[],"data":[]},{"key":"b493h","text":"- Staining of human PBMC or ISOLATED SUBSETS with Cell Proliferation Dye-eFluor\u2122 670 (CPD-eFluor670) for cell proliferation evaluation by Flow Cytometry","type":"unstyled","depth":0,"inlineStyleRanges":[],"entityRanges":[],"data":[]}],"entityMap":[]}
?. Place of FICOLL in a 15 mL conical tube.
3 mL
?. CAREFULLY  layer  of diluted blood on the FICOLL with a glass Pasteur Pipette to a final volume of 15 ml as shown in the figure below.
12 mL
?. Centrifuge samples  without break.
Centrifuge: 400 34, 40 min
?. After centrifugation, take out the tubes carefully to not disturb the mononuclear cell layer that appears as a white, cloudy band between the plasma and FICOLL as shown in the figure below.
?. Carefully with a glass Pasteur pipette transfer mononuclear lymphocyte cell layer to another 15 ml conical tube.
?. Wash the isolated PBMC with PBS/FBS 2% to a final volume of  and centrifuge at at RT.
10 mL
Centrifuge: 300 34, 10 min
?. Remove supernatants, resuspend pellet in  of Lysis Buffer and add another  of Lysis Buffer. Immediately centrifuge the tubes at  at RT.
1 mL
9 mL
Centrifuge: 100 34, 10 min
{"blocks":[{"key":"7s7be","text":"This recipe is used in the following protocols:","type":"unstyled","depth":0,"inlineStyleRanges":[],"entityRanges":[],"data":[]},{"key":"bmloc","text":"","type":"unstyled","depth":0,"inlineStyleRanges":[],"entityRanges":[],"data":[]},{"key":"1ifqv","text":"- PBMC- 01a - Isolation of Human PBMC from Buffy Coat","type":"unstyled","depth":0,"inlineStyleRanges":[{"length":14,"offset":0,"style":"bold"}],"entityRanges":[],"data":[]},{"key":"cr04n","text":"- PBMC- 01b - Isolation of Human PBMC from Whole Blood","type":"unstyled","depth":0,"inlineStyleRanges":[{"length":14,"offset":0,"style":"bold"}],"entityRanges":[],"data":[]},{"key":"347o3","text":"- PBMC- 02 - CD4+ T cell Isolation from PBMC with \u201cDynabeads CD4 Positive Isolation Kit\u201d","type":"unstyled","depth":0,"inlineStyleRanges":[{"length":13,"offset":0,"style":"bold"}],"entityRanges":[],"data":[]},{"key":"abstj","text":"- PBMC- 03 - TEFF+TREG Isolation from PBMC with \u201cMiltenyi CD4+CD25+ Regulatory T cell Isolation Kit\u201d","type":"unstyled","depth":0,"inlineStyleRanges":[{"length":12,"offset":0,"style":"bold"}],"entityRanges":[],"data":[]},{"key":"6lj08","text":"- PMN- 01a - Isolation of Human PMN from Buffy Coat","type":"unstyled","depth":0,"inlineStyleRanges":[{"length":13,"offset":0,"style":"bold"}],"entityRanges":[],"data":[]},{"key":"es9kq","text":"- PMN- 01b - Isolation of Human PMN from Whole Blood","type":"unstyled","depth":0,"inlineStyleRanges":[{"length":13,"offset":0,"style":"bold"}],"entityRanges":[],"data":[]},{"key":"ued6","text":"","type":"unstyled","depth":0,"inlineStyleRanges":[],"entityRanges":[],"data":[]}],"entityMap":[]}
?. Remove supernatant and resuspend pellet in  PBS/FBS 2% and centrifuge at  at RT.
10 mL
Centrifuge: 300 34, 10 min
?. Remove supernatant and resuspend the obtained pellet in  of RPMI/FBS 10% for cell counting.
10 mL
?. For manual cell count use Türk solution for checking purity. Follow protocol CELL COUNT- 02
{"blocks":[{"key":"9lo9p","text":"This recepe is used in the following protocols:","type":"unstyled","depth":0,"inlineStyleRanges":[],"entityRanges":[],"data":[]},{"key":"e9i8k","text":"","type":"unstyled","depth":0,"inlineStyleRanges":[],"entityRanges":[],"data":[]},{"key":"b6nn5","text":"- PBMC- 01a - Isolation of Human PBMC from Buffy Coat","type":"unstyled","depth":0,"inlineStyleRanges":[{"length":14,"offset":0,"style":"bold"}],"entityRanges":[],"data":[]},{"key":"6p1pt","text":"- PBMC- 01b - Isolation of Human PBMC from Whole Blood","type":"unstyled","depth":0,"inlineStyleRanges":[{"length":14,"offset":0,"style":"bold"}],"entityRanges":[],"data":[]},{"key":"b8cq7","text":"- PBMC- 02 - CD4+ T cell Isolation from PBMC with \u201cDynabeads CD4 Positive Isolation Kit\u201d","type":"unstyled","depth":0,"inlineStyleRanges":[{"length":13,"offset":0,"style":"bold"}],"entityRanges":[],"data":[]},{"key":"csp0r","text":"- PBMC- 03 - TEFF+TREG Isolation from PBMC with \u201cMiltenyi CD4+CD25+ Regulatory T cell Isolation Kit\u201d","type":"unstyled","depth":0,"inlineStyleRanges":[{"length":12,"offset":0,"style":"bold"}],"entityRanges":[],"data":[]},{"key":"f999s","text":"- PMN- 01a - Isolation of Human PMN from Buffy Coat","type":"unstyled","depth":0,"inlineStyleRanges":[{"length":13,"offset":0,"style":"bold"}],"entityRanges":[],"data":[]},{"key":"d5k2d","text":"- PMN- 01b - Isolation of Human PMN from Whole Blood","type":"unstyled","depth":0,"inlineStyleRanges":[{"length":13,"offset":0,"style":"bold"}],"entityRanges":[],"data":[]},{"key":"8opph","text":"","type":"unstyled","depth":0,"inlineStyleRanges":[],"entityRanges":[],"data":[]},{"key":"aui15","text":"","type":"unstyled","depth":0,"inlineStyleRanges":[],"entityRanges":[],"data":[]}],"entityMap":[]}
?. OPTIONAL STEPFor automatic cell count with Cellometer machine use Trypan Blue. Follow protocol CELL COUNT- 03.
{"blocks":[{"key":"ekvmp","text":"This recepe is used in the following protocols:","type":"unstyled","depth":0,"inlineStyleRanges":[],"entityRanges":[],"data":[]},{"key":"ebip5","text":"","type":"unstyled","depth":0,"inlineStyleRanges":[],"entityRanges":[],"data":[]},{"key":"bae3c","text":"- PBMC- 01a - Isolation of Human PBMC from Buffy Coat","type":"unstyled","depth":0,"inlineStyleRanges":[{"length":14,"offset":0,"style":"bold"}],"entityRanges":[],"data":[]},{"key":"9h426","text":"- PBMC- 01b - Isolation of Human PBMC from Whole Blood","type":"unstyled","depth":0,"inlineStyleRanges":[{"length":14,"offset":0,"style":"bold"}],"entityRanges":[],"data":[]},{"key":"eadol","text":"- PBMC- 02 - CD4+ T cell Isolation from PBMC with \u201cDynabeads CD4 Positive Isolation Kit\u201d","type":"unstyled","depth":0,"inlineStyleRanges":[{"length":13,"offset":0,"style":"bold"}],"entityRanges":[],"data":[]},{"key":"4mvil","text":"- PBMC- 03 - TEFF+TREG Isolation from PBMC with \u201cMiltenyi CD4+CD25+ Regulatory T cell Isolation Kit\u201d","type":"unstyled","depth":0,"inlineStyleRanges":[{"length":12,"offset":0,"style":"bold"}],"entityRanges":[],"data":[]},{"key":"c38fg","text":"- PMN- 01a - Isolation of Human PMN from Buffy Coat","type":"unstyled","depth":0,"inlineStyleRanges":[{"length":13,"offset":0,"style":"bold"}],"entityRanges":[],"data":[]},{"key":"b27co","text":"- PMN- 01b - Isolation of Human PMN from Whole Blood","type":"unstyled","depth":0,"inlineStyleRanges":[{"length":13,"offset":0,"style":"bold"}],"entityRanges":[],"data":[]},{"key":"9pi2","text":"","type":"unstyled","depth":0,"inlineStyleRanges":[],"entityRanges":[],"data":[]}],"entityMap":[]}
?. If needed, check the purity of PBMC suspension by using morphological parameter of the flow cytometer. For this test 0.5x106 PBMC in 500 µl of PBS are enough.
?. Expected results
VIABILITY - The expected viability by Trypan Blue should be ≥90 %.PURITY - The PBMC suspension obtained should contain at least 80% of lymphocytes, 10-15% of monocytes and few contaminant PMN cells (≤ 5%) as confirmed by flow cytometry.YIELD - The expected amount of PBMCs should be ± 100x106 starting from 25 ml of buffy coat.